| Lennox-Gastaut Syndrome
Epidiolex vs Qudexy XR
Side-by-side clinical, coverage, and cost comparison for lennox-gastaut syndrome.Deep comparison between: Epidiolex vs Qudexy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQudexy has a higher rate of injection site reactions vs Epidiolex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qudexy but not Epidiolex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Epidiolex
Qudexy
At A Glance
Oral
Twice daily
Cannabinoid antiepileptic
Oral
Once daily
Broad-spectrum anticonvulsant
Indications
- Lennox-Gastaut syndrome
- Infantile Severe Myoclonic Epilepsy
- Tuberous Sclerosis
- Seizures, Focal
- Generalized seizures
- Lennox-Gastaut syndrome
- Migraine Disorders
Dosing
Lennox-Gastaut syndrome, Infantile Severe Myoclonic Epilepsy Starting 2.5 mg/kg orally twice daily (5 mg/kg/day); increase after 1 week to maintenance 5 mg/kg twice daily (10 mg/kg/day); may increase up to maximum 10 mg/kg twice daily (20 mg/kg/day) in weekly increments based on response and tolerability.
Tuberous Sclerosis Starting 2.5 mg/kg orally twice daily (5 mg/kg/day); increase weekly by 2.5 mg/kg twice daily (5 mg/kg/day) as tolerated to recommended maintenance 12.5 mg/kg twice daily (25 mg/kg/day).
Seizures, Focal, Generalized seizures, Lennox-Gastaut syndrome Monotherapy (adults and peds >=10 years): 400 mg orally once daily, titrated over 6 weeks from 50 mg/day; peds 2-9 years: weight-based 150-400 mg/day once daily. Adjunctive (adults): 200 to 400 mg once daily; adjunctive (peds 2-16 years): approximately 5 to 9 mg/kg once daily, not to exceed 400 mg/day.
Migraine Disorders 100 mg orally once daily for patients 12 years of age and older, titrated over 4 weeks from 25 mg/day.
Contraindications
- History of hypersensitivity to cannabidiol or any excipient in EPIDIOLEX
- History of hypersensitivity reaction to topiramate, QUDEXY XR, or any inactive ingredient
Adverse Reactions
Most common (>=10%) Somnolence, decreased appetite, diarrhea, transaminase elevations, fatigue, malaise, asthenia, rash, insomnia, pyrexia, vomiting
Serious Hepatic injury, somnolence and sedation, suicidal behavior and ideation, hypersensitivity reactions
Most common (>=10%) Paresthesia, somnolence, dizziness, weight loss, anorexia, speech disorders/related speech problems, psychomotor slowing, nervousness, vision abnormal
Serious Acute myopia and secondary angle closure glaucoma, visual field defects, oligohydrosis and hyperthermia, metabolic acidosis, suicidal behavior and ideation, cognitive/neuropsychiatric adverse reactions, decrease in bone mineral density, negative effects on growth, DRESS/multiorgan hypersensitivity, serious skin reactions, anaphylaxis and angioedema, hyperammonemia and encephalopathy, kidney stones, hypothermia with concomitant valproic acid
Postmarketing Hepatic failure, hepatitis, pancreatitis, bullous skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), pemphigus, maculopathy, nephrocalcinosis
Pharmacology
Cannabidiol is a phytocannabinoid antiepileptic; its precise mechanisms of anticonvulsant action in humans are unknown and do not appear to involve interaction with cannabinoid receptors.
Topiramate blocks voltage-dependent sodium channels, augments GABA-A receptor activity, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits carbonic anhydrase isozymes II and IV; the precise mechanisms underlying its anticonvulsant and preventive migraine effects are unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Epidiolex
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (0/12)
Qudexy
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Epidiolex
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (0/8)
Qudexy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Epidiolex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Qudexy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Epilepsy (Seizures): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Qudexy.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EpidiolexView full Epidiolex profile
QudexyView full Qudexy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.